Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2021-11-18 Regulatory Filings
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH
Regulatory Filings Classification · 100% confidence The document is a press release dated November 18, 2021, announcing positive results from the FNIH NIMBLE Study regarding GENFIT's NIS4® technology for identifying NASH patients. It details study findings, includes quotes from the CEO and a key physician, and provides background information on FNIH, NIMBLE, and GENFIT. This format—a news announcement highlighting recent achievements, study results, or corporate milestones—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate news. Since it focuses on the announcement of study results and their implications rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these announcements often accompany or precede formal financial reporting periods, or serve as major operational updates. It is not a 10-K (Annual Report), IR (Interim Report), or CT (Call Transcript). It is a direct announcement of results, fitting the ER definition best, even though the results are clinical/scientific rather than purely financial highlights.
2021-11-18 English
GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program
Regulatory Filings Classification · 95% confidence The document is a press release dated November 09, 2021, announcing a clinical trial milestone: 'GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program'. It details the study design, scientific rationale, and includes forward-looking statements and contact information typical of corporate news releases regarding operational updates. This type of announcement, focusing on clinical trial progress and pipeline development, is best classified as an Investor Presentation (IP) if it were a detailed deck, or more generally, a corporate announcement. Since it is a press release detailing specific operational/pipeline news rather than a formal regulatory filing (like 10-K or IR) or a general regulatory notice (RNS), and it is not a transcript (CT) or a formal earnings release (ER), it fits best under the general category for investor-focused updates that aren't strictly financial reports or formal regulatory filings. However, given the options, this is a specific operational update. It is not a formal Earnings Release (ER) as it doesn't focus on period financials, nor is it a Call Transcript (CT). It is a detailed update on drug development, which often accompanies or substitutes for an Investor Presentation (IP) in the form of a press release. Given the context of pipeline progress, IP is a strong candidate, but since it is a news announcement, 'RNS' (Regulatory Filings/General Announcements) is often used for press releases that don't fit other specific categories. Since it is a detailed announcement about clinical progress, which is key investor information, and it is not a formal report, I will classify it as an Investor Presentation (IP) as it serves that function, or RNS if IP is too specific for a press release format. Given the detailed nature of the clinical update, IP is more descriptive of the content's purpose than the general RNS fallback. However, looking at the definitions, 'IP' is 'Investor Presentation' (implying slides/deck). This is a press release. Press releases announcing clinical milestones are frequently categorized as RNS (Regulatory News Service/General Announcement) when they don't fit ER, CT, or specific financial reports. I will use RNS as the most appropriate general announcement category for a clinical trial update press release.
2021-11-09 English
GENFIT : première consultation du premier patient pour l’évaluation de NTZ chez des sujets présentant une dysfonction hépatique dans le cadre du programme ACLF
Regulatory Filings Classification · 93% confidence The document is a press release dated November 9, 2021, announcing a clinical development milestone: the first patient consultation for a Phase 1 study evaluating Nitazoxanide (NTZ) for Acute on Chronic Liver Failure (ACLF). It details the study design, the medical need, and provides commentary from a physician and the CEO. It also mentions future results availability (Q3 2022) and updates on other pipeline products (elafibranor, GFT1575). This content is characteristic of an announcement detailing operational progress, specifically related to clinical trials and pipeline updates, rather than a formal regulatory filing like a 10-K, a quarterly report (IR), or a formal earnings release (ER). Since it is a press release announcing a specific clinical event and progress, it fits best under the general category of Investor Relations material, but given the specific options, it is a communication about the company's operations and pipeline. It is not a Call Transcript (CT), Director's Dealing (DIRS), or a Dividend Notice (DIV). It is a general corporate announcement. In the context of the provided definitions, this type of update, which is not a formal financial report (10-K, IR) or a specific regulatory filing like DIRS or DIV, often falls under general corporate communication. However, since it is a detailed update on clinical progress and pipeline strategy, it is most closely aligned with an Investor Presentation (IP) in terms of content depth, although it is formatted as a press release. Given the options, and recognizing this is a detailed update on R&D progress intended for investors, 'Investor Presentation' (IP) is the closest fit for substantive content, although 'Regulatory Filings' (RNS) is a possibility if it were a less specific announcement. Since it is a detailed update on a clinical trial initiation, it functions similarly to an investor update presentation. I will classify it as an Investor Presentation (IP) due to the detailed scientific and strategic information provided, which is typical of an IP, even if the format is a press release.
2021-11-09 French
GENFIT: Third Quarter 2021 Financial Information
Earnings Release Classification · 100% confidence The document is explicitly titled "PRESS RELEASE" and focuses on providing key financial metrics for a specific period: "GENFIT: Third Quarter 2021 Financial Information" and "Revenues for the first nine months of 2021". It details the cash position as of September 30, 2021, and revenues for the first nine months of 2021. This content structure—a brief announcement of key period results, often released before a more comprehensive report—aligns perfectly with the definition of an Earnings Release (ER). It is not a full Annual Report (10-K), an Interim Report (IR) which is usually more comprehensive, or a Call Transcript (CT). Since it is a press release announcing results, it is classified as ER. 9M 2021
2021-11-08 English
GENFIT : Information financière du troisième trimestre 2021
Earnings Release Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces "Information financière du troisième trimestre 2021" (Third Quarter 2021 Financial Information). It provides key financial highlights (cash position, revenue) for the nine-month period ending September 30, 2021. This structure—a brief announcement summarizing key figures for a specific interim period—is characteristic of an Earnings Release (ER). It is not the comprehensive Interim/Quarterly Report (IR) itself, but the initial announcement of the results. The document length is moderate (8275 chars), but its format is clearly an announcement summarizing results rather than the full statutory report. 9M 2021
2021-11-08 French
New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®
Regulatory Filings Classification · 100% confidence The document is a press release dated November 02, 2021, announcing that GENFIT will present new clinical data on its compound elafibranor at the AASLD The Liver Meeting® 2021. It details the study objectives, results (safety, tolerability, pharmacokinetics), and provides specific poster presentation details. This format—a news announcement summarizing research findings and upcoming presentations, rather than the full financial report (10-K), a comprehensive quarterly report (IR), or just the presentation slides (IP)—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical updates. Since it focuses on clinical data presentation and not quarterly financial performance highlights, it fits best as a general announcement. Given the options, and recognizing that this is a formal announcement of clinical progress and upcoming presentation, it is closest to an Earnings Release (ER) if we interpret ER broadly as a periodic results announcement, or potentially a Regulatory Filing (RNS) if it doesn't fit other categories well. However, the content is a direct announcement of clinical trial results and presentation schedule, which often accompanies or substitutes for a formal earnings report in biotech/pharma. Since it is not a full financial report, nor a proxy statement, nor a management discussion, and it is a formal announcement of data, 'ER' (Earnings Release, often used for key periodic announcements) is a plausible fit, but 'RNS' (Regulatory Filings/General Announcement) is the safest fallback for non-standard corporate news. Given the structure is a press release announcing scientific data presentation, and it is not a full financial report, I will classify it as a general announcement/regulatory filing (RNS) as it doesn't strictly align with the core definitions of ER (which usually focuses on P&L/Balance Sheet highlights) or IP (which is the presentation itself).
2021-11-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.